Application Detail
Description of Medical Service
Brexucabtagene autoleucel is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapeutic process, involving harvesting, modifying, expanding and re-infusing a patient's own immune T-cells, to target and destroy certain cancerous cells.Description of Medical Condition
Relapsed or refractory mantle cell lymphoma is an aggressive subtype of non-Hodgkin lymphomaReason for Application
Highly Specialised Therapy - National Health Reform AgreementMedical Service Type
Therapeutic technologyPrevious Application Number/s
Not ApplicableAssociated Documentation
Application Form
Application Form (PDF 1088 KB)Application Form (Word 345 KB)
Consultation Survey
Consultation Survey (PDF 559 KB)Consultation Survey (Word 71 KB)
PICO Confirmation
-Assessment Report
-Public Summary Document
Public Summary Document (PDF 929 KB)Public Summary Document (Word 531 KB)
Meetings for this Application
PASC
Expedited – Bypassing PASCESC
10-11 June 2021MSAC
29-30 July 202129 July 2023